Archive
Every story, newest first.
Wednesday, November 4, 2026
Infrastructure
Vestel Elektronik and Anadolu Group Holding have signed agreements to sell their combined 46 percent stake in Turkish electric vehicle maker TOGG to the Turkey Wealth Fund and Turkcell for 184 million euros each, 368 million euros in total.
Infrastructure
Saudi Arabia's Public Investment Fund has raised the equivalent of 3 billion dollars in dual tranche credit facilities guaranteed by SACE, Italy's export credit agency, from a syndicate of 25 international banks.
Infrastructure
Nigeria's NNPC is likely to float between 5 percent and 10 percent of its equity in an initial public offering aimed mainly at domestic investors, its chief executive told Reuters at ADIPEC, with preparations expected to take at least all of 2027.
Infrastructure
NextEra Energy and Dominion Energy have accepted 101 of 117 conditions proposed by Virginia regulators for their 67 billion dollar merger, and another 13 with modifications, ahead of the State Corporation Commission hearing.
Life Sciences
Novartis has terminated its August 2025 collaboration with BioArctic, which carried a 30 million dollar upfront payment and up to 772 million dollars in milestones, 14 months after signing.
Life Sciences
A child in Lewis County, New York, has died in the state's measles outbreak, its first measles associated death in more than 30 years, state officials announced on November 2.
Life Sciences
Minghui Pharmaceutical will receive 110 million dollars upfront from ASKA Pharmaceutical for exclusive Japanese rights to MHB018A, its IGF-1R antibody for thyroid eye disease.
Life Sciences
Also notable in life sciences: Pfizer's chief executive expects no change to most favoured nation deals after the midterms, federal agencies move to head off a clash with state clinical AI programmes, and Lilly's pipeline churn draws a closer look.
Life Sciences
Bayer raised its 2026 group earnings outlook to 9.8 billion to 10.3 billion euros after pharmaceuticals sales rose 8 percent in the third quarter to 4.68 billion euros.
Life Sciences
Amgen reported third quarter revenue of 10.4 billion dollars, up 8 percent year on year, and raised full year 2026 guidance to 38.9 billion to 39.7 billion dollars.